Targeting Common Disease Pathomechanisms to Treat Amyotrophic Lateral Sclerosis

Overview

Journal Nat Rev Neurol

Specialty Neurology

Date 2025 Jan 1

PMID 39743546

Authors

Kiterie M E Faller

Helena Chaytow

Thomas H Gillingwater

Affiliations

Soon will be listed here.

Abstract

The motor neuron disease amyotrophic lateral sclerosis (ALS) is a devastating condition with limited treatment options. The past few years have witnessed a ramping up of translational ALS research, offering the prospect of disease-modifying therapies. Although breakthroughs using gene-targeted approaches have shown potential to treat patients with specific disease-causing mutations, the applicability of such therapies remains restricted to a minority of individuals. Therapies targeting more general mechanisms that underlie motor neuron pathology in ALS are therefore of considerable interest. ALS pathology is associated with disruption to a complex array of key cellular pathways, including RNA processing, proteostasis, metabolism and inflammation. This Review details attempts to restore cellular homeostasis by targeting these pathways in order to develop effective, broadly-applicable ALS therapeutics.

References

Feldman E, Goutman S, Petri S, Mazzini L, Savelieff M, Shaw P . Amyotrophic lateral sclerosis. Lancet. 2022; 400(10360):1363-1380. PMC: 10089700. DOI: 10.1016/S0140-6736(22)01272-7. View

Marin B, Fontana A, Arcuti S, Copetti M, Boumediene F, Couratier P . Age-specific ALS incidence: a dose-response meta-analysis. Eur J Epidemiol. 2018; 33(7):621-634. DOI: 10.1007/s10654-018-0392-x. View

Mejzini R, Flynn L, Pitout I, Fletcher S, Wilton S, Akkari P . ALS Genetics, Mechanisms, and Therapeutics: Where Are We Now?. Front Neurosci. 2019; 13:1310. PMC: 6909825. DOI: 10.3389/fnins.2019.01310. View

Andrews J, Jackson C, Heiman-Patterson T, Bettica P, Brooks B, Pioro E . Real-world evidence of riluzole effectiveness in treating amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2020; 21(7-8):509-518. DOI: 10.1080/21678421.2020.1771734. View

Pioro E, Brooks B, Cummings J, Schiffer R, Thisted R, Wynn D . Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect. Ann Neurol. 2010; 68(5):693-702. DOI: 10.1002/ana.22093. View

Finkel R, Chiriboga C, Vajsar J, Day J, Montes J, De Vivo D . Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study. Lancet. 2016; 388(10063):3017-3026. DOI: 10.1016/S0140-6736(16)31408-8. View

Miller T, Cudkowicz M, Genge A, Shaw P, Sobue G, Bucelli R . Trial of Antisense Oligonucleotide Tofersen for ALS. N Engl J Med. 2022; 387(12):1099-1110. DOI: 10.1056/NEJMoa2204705. View

Chaytow H, Faller K, Huang Y, Gillingwater T . Spinal muscular atrophy: From approved therapies to future therapeutic targets for personalized medicine. Cell Rep Med. 2021; 2(7):100346. PMC: 8324491. DOI: 10.1016/j.xcrm.2021.100346. View

Day J, Howell K, Place A, Long K, Rossello J, Kertesz N . Advances and limitations for the treatment of spinal muscular atrophy. BMC Pediatr. 2022; 22(1):632. PMC: 9632131. DOI: 10.1186/s12887-022-03671-x. View

10.

Hardiman O, Al-Chalabi A, Chio A, Corr E, Logroscino G, Robberecht W . Amyotrophic lateral sclerosis. Nat Rev Dis Primers. 2017; 3:17071. DOI: 10.1038/nrdp.2017.71. View

11.

Goutman S, Hardiman O, Al-Chalabi A, Chio A, Savelieff M, Kiernan M . Emerging insights into the complex genetics and pathophysiology of amyotrophic lateral sclerosis. Lancet Neurol. 2022; 21(5):465-479. PMC: 9513754. DOI: 10.1016/S1474-4422(21)00414-2. View

12.

Van Nostrand E, Freese P, Pratt G, Wang X, Wei X, Xiao R . A large-scale binding and functional map of human RNA-binding proteins. Nature. 2020; 583(7818):711-719. PMC: 7410833. DOI: 10.1038/s41586-020-2077-3. View

13.

Fernandopulle M, Lippincott-Schwartz J, Ward M . RNA transport and local translation in neurodevelopmental and neurodegenerative disease. Nat Neurosci. 2021; 24(5):622-632. PMC: 8860725. DOI: 10.1038/s41593-020-00785-2. View

14.

Nikom D, Zheng S . Alternative splicing in neurodegenerative disease and the promise of RNA therapies. Nat Rev Neurosci. 2023; 24(8):457-473. DOI: 10.1038/s41583-023-00717-6. View

15.

Butti Z, Patten S . RNA Dysregulation in Amyotrophic Lateral Sclerosis. Front Genet. 2019; 9:712. PMC: 6349704. DOI: 10.3389/fgene.2018.00712. View

16.

DeJesus-Hernandez M, Mackenzie I, Boeve B, Boxer A, Baker M, Rutherford N . Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011; 72(2):245-56. PMC: 3202986. DOI: 10.1016/j.neuron.2011.09.011. View

17.

Kumar V, Hasan G, Hassan M . Unraveling the Role of RNA Mediated Toxicity of Repeats in C9-FTD/ALS. Front Neurosci. 2018; 11:711. PMC: 5736982. DOI: 10.3389/fnins.2017.00711. View

18.

Ling S, Polymenidou M, Cleveland D . Converging mechanisms in ALS and FTD: disrupted RNA and protein homeostasis. Neuron. 2013; 79(3):416-38. PMC: 4411085. DOI: 10.1016/j.neuron.2013.07.033. View

19.

Freibaum B, Chitta R, High A, Taylor J . Global analysis of TDP-43 interacting proteins reveals strong association with RNA splicing and translation machinery. J Proteome Res. 2009; 9(2):1104-20. PMC: 2897173. DOI: 10.1021/pr901076y. View

20.

Polymenidou M, Lagier-Tourenne C, Hutt K, Huelga S, Moran J, Liang T . Long pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43. Nat Neurosci. 2011; 14(4):459-68. PMC: 3094729. DOI: 10.1038/nn.2779. View